Geode Capital Management LLC Has $2.51 Million Stock Position in uniQure (NASDAQ:QURE)

Geode Capital Management LLC lifted its holdings in shares of uniQure (NASDAQ:QURE) by 1.3% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 508,602 shares of the biotechnology company’s stock after buying an additional 6,362 shares during the period. Geode Capital Management LLC owned about 1.04% of uniQure worth $2,509,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of QURE. abrdn plc raised its holdings in shares of uniQure by 381.7% during the 3rd quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock worth $9,510,000 after buying an additional 1,528,581 shares in the last quarter. Point72 Asset Management L.P. raised its holdings in shares of uniQure by 336.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock worth $4,816,000 after buying an additional 752,889 shares in the last quarter. FMR LLC raised its holdings in shares of uniQure by 8,056.6% during the 3rd quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock worth $1,728,000 after buying an additional 346,274 shares in the last quarter. Privium Fund Management B.V. raised its holdings in shares of uniQure by 16.3% during the 3rd quarter. Privium Fund Management B.V. now owns 744,916 shares of the biotechnology company’s stock worth $3,672,000 after buying an additional 104,500 shares in the last quarter. Finally, Walleye Capital LLC bought a new stake in uniQure during the 3rd quarter worth $444,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

Insider Activity at uniQure

In related news, CEO Matthew C. Kapusta sold 3,418 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $7.63, for a total transaction of $26,079.34. Following the transaction, the chief executive officer now directly owns 597,915 shares of the company’s stock, valued at approximately $4,562,091.45. This represents a 0.57 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.74% of the stock is owned by corporate insiders.

uniQure Trading Down 2.4 %

NASDAQ QURE opened at $17.64 on Wednesday. uniQure has a 12 month low of $3.73 and a 12 month high of $19.18. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The business’s 50-day moving average price is $10.61 and its two-hundred day moving average price is $7.75. The firm has a market capitalization of $859.83 million, a PE ratio of -3.56 and a beta of 0.41.

uniQure (NASDAQ:QURE) last announced its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, beating the consensus estimate of ($1.12) by $0.21. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The company had revenue of $2.29 million for the quarter, compared to analyst estimates of $2.73 million. On average, analysts expect that uniQure will post -3.82 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on QURE. HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of uniQure in a research report on Tuesday, December 10th. Royal Bank of Canada boosted their price objective on uniQure from $14.00 to $20.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 11th. Raymond James upgraded uniQure from an “outperform” rating to a “strong-buy” rating and boosted their price objective for the stock from $20.00 to $52.00 in a research report on Tuesday, December 10th. The Goldman Sachs Group boosted their price objective on uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a research report on Thursday, December 12th. Finally, StockNews.com upgraded uniQure to a “sell” rating in a research report on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $33.88.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.